Back to Journals » Biologics: Targets and Therapy » Volume 4

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

Total article views   Abstract views HTML views PDF downloads Totals
10,817 Dovepress* 10,817 0+ 2,564 10,817
Totals 10,817 0 2,564 10,817
*Since 30 April 2010
+Since July 2016

View citations on Google Scholar